US2015374715A1PendingUtilityA1
Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection
Est. expiryNov 16, 2026(~0.3 yrs left)· nominal 20-yr term from priority
A61P 31/16A61P 43/00A61P 29/00A61K 31/7012A61K 31/215A61K 31/343A61K 31/5585A61K 31/5578A61K 47/6951A61P 11/00A61K 31/5575A61K 47/48969
46
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is directed to the use of EP2 and/or EP4 agonists as therapeutics for the treatment of diseases associated with influenza A viruses, such as for example H5N1 and mutations thereof.
Claims
exact text as granted — not AI-modified1 - 20 . (canceled)
21 : A method of inhibiting the release of overstimulated cytokines and/or chemokines in a subject, said method comprising administering to a subject in need thereof an amount of beraprost effective to inhibit the release of overstimulated cytokines and/or chemokines.
22 : The method of claim 21 , wherein said cytokines and/or chemokines are inflammatory cytokines or chemokines.
23 : The method of claim 21 , wherein the overstimulated cytokines comprise TNFα.
24 : The method of claim 21 , wherein the overstimulated cytokines comprise IFN-gamma.
25 : The method of claim 21 , wherein said beraprost is a pharmaceutically acceptable salt or cyclodextrin clathrate.Join the waitlist — get patent alerts
Track US2015374715A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.